View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 4, 2021updated 12 Jul 2022 11:13am

The CenterTX to deploy Deep Lens’ AI-based solution for clinical trials

VIPER can identify qualified patients for clinical trials by integrating into The CenterTX’s molecular data feeds directly.

The Center for Cancer and Blood Disorders (The CenterTX) in the US is set to deploy Deep Lens’ artificial intelligence (AI)-based clinical trial screening and enrolment solution VIPER.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Using Cloud-based technology, VIPER will facilitate, triage, and accelerate the clinical trial recruitment process.

Through its partnership with Deep Lens, The CenterTX will broaden its clinical trial offering by improving efficiencies related to recruitment and expanding the number of available trials for eligible subjects.

The CenterTX serves patients across ten locations in North Texas.

The CenterTX CEO Barry Russo said: “We are a forward-looking practice that takes pride in our ability to offer our patient community a robust suite of services and cutting-edge treatment options designed to meet their individual needs.

“We are very excited to integrate VIPER into our clinical trial programme, as it will not only help assist in growing our research capabilities, but it will also provide the practice with quality metrics, improved operational support and present our care teams a more effective method by which to match patients to trials.”

By integrating directly into The CenterTX’s EMR (VieCure), molecular data feeds and pathology feeds, VIPER will automatically identify qualified patients for clinical trials.

Deep Lens chief revenue officer Greg Andreola said: “This collaboration will provide The CenterTX the ability to accelerate enrolment in clinical trials and will help reinforce its leadership in the oncology community by offering an increased number of precision medicine trials.”

Last month, cancer care network Oncology and Hematology Specialists collaborated with Deep Lens to integrate VIPER.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena